Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors

NCT01337765 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01337765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01337765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
July 8, 2011
Completion date
March 22, 2013
Enrollment
29 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, unspecified adult solid tumor, protocol specific